The Fat-Loss Lineup
One incretin base, optional adjuncts: how weight protocols actually get assembled.
Why this stack
Fat-loss stacks are built on one rule: a single incretin base, never two. Semaglutide is the conservative pick with the deepest human record, tirzepatide adds the GIP receptor and beat it head to head, and retatrutide is the aggressive triple agonist still in trials. Adjuncts ride alongside without touching the incretin axis: L-carnitine for fatty-acid transport into mitochondria, AOD-9604 as the GH fragment studied for lipolysis without IGF-1 elevation.
The protocol at a glance
Community-reported maintenance amounts, derived live from each compound's protocol page. Click through for titration phases, reconstitution steps and the evidence grading behind every number.
Pick ONE incretin base
| Compound | Dose | Frequency | Recon | Units/injection |
|---|---|---|---|---|
| Semaglutide Human trial data |
2.4 mg | Once weekly | 10 mg + 1 mL | 24 units (0.24 mL) |
| Tirzepatide Human trial data |
10 mg | Once weekly | 10 mg + 1 mL | 100 units (1.0 mL) |
| Retatrutide Human trial data |
8 mg | Once weekly | 10 mg + 1 mL | 80 units (0.8 mL) |
Optional adjuncts
| Compound | Dose | Frequency | Recon | Units/injection |
|---|---|---|---|---|
| L-Carnitine Human trial data |
500 mg IM | Once to twice weekly | Pre-mixed | 1 mL of 500 mg/mL pre-mixed solution |
| AOD-9604 Human trial data |
500 mcg | Once daily, morning | 5 mg + 0.5 mL | 5 units (0.05 mL) |
How it is run
- Never stack two GLP-1 agonists; switch bases only with a washout and a reason.
- The base runs weekly; adjuncts run on their own daily or near-daily schedules.
- Escalate the base per its titration table and let tolerability set the pace.
- Protein and resistance training are what keep the loss from being muscle; the lifestyle section on each protocol page is not decoration.
What the components report
Reported upsides
- Semaglutide: Significant weight loss in clinical trials
- Semaglutide: Improved glycaemic control and HbA1c
- Tirzepatide: Greater weight loss than semaglutide in head-to-head trials
- Tirzepatide: Dual GIP/GLP-1 action for enhanced metabolic effects
- Retatrutide: Triple agonist (GIP/GLP-1/glucagon) for enhanced fat loss
- Retatrutide: Phase 2 showed up to 24% body weight reduction
- L-Carnitine: Approved for carnitine deficiency replacement
- L-Carnitine: Supports fatty acid transport into mitochondria
- AOD-9604: Fragment of growth hormone targeting fat metabolism
- AOD-9604: No effect on blood sugar or IGF-1 levels
Cautions
- Semaglutide: Nausea, vomiting and diarrhoea (common on escalation)
- Semaglutide: Reduced appetite (intended effect)
- Tirzepatide: GI effects similar to semaglutide (nausea, diarrhoea)
- Tirzepatide: Reduced appetite
- Retatrutide: GI side effects more common than single agonists
- Retatrutide: Nausea and diarrhoea during escalation
- L-Carnitine: GI effects and body odour at higher doses (from label)
- L-Carnitine: Injection site reactions with IM administration
- AOD-9604: Injection site reactions
- AOD-9604: Headache reported occasionally
Pulled from each compound's benefits and side effects section. Individual responses vary. Not medical advice.
Track this stack
The free tracker logs each component on its own schedule, rotates injection sites across the whole stack, and counts down every vial with a reorder heads-up.
+ Semaglutide+ Tirzepatide+ Retatrutide+ L-Carnitine+ AOD-9604
Sourcing the stack
Same rule as every protocol page: the batch COA matters more than the price. Summit Research Supply is the supplier we feature; code PEPDOSE applies to each component.
Semaglutide →Tirzepatide →Retatrutide →L-Carnitine →AOD-9604 →
Summit links are affiliate links. Our COA checklist applies the same way to any vendor.
